Anti-EGFR antibodies may get benefit as first-line treatment in metastatic right-sided colon cancer

被引：0
|
作者：
Elbaiomy, M. [1 ]
Elsayed, A. [2 ]
Akl, T. [1 ]
机构：
[1] Mansoura Univ, Oncol Ctr, Mansoura, Egypt
[2] Fac Med, Mansoura, Egypt
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.272
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-182
引用
收藏
页码：S314 / S315
页数：2
相关论文
共 50 条
  • [21] BUDGETARY IMPACT OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER BASED ON XELOX plus ANTI-VEGF OR XELOX plus ANTI-EGFR
    Gomez, E.
    Torrecillas, L.
    Cervantes, L.
    VALUE IN HEALTH, 2011, 14 (07) : A543 - A543
  • [22] First-line metastatic cancer of the colon
    Raoul, JL
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2003, 27 (05): : B150 - B153
  • [23] Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis
    Stock, Gustavo
    Aguiar, Pedro, Jr.
    Santoro, Ilka
    Tadokoro, Hakaru
    De Mello, Ramon
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S333 - S334
  • [24] First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
    Airoldi, Marco
    Bartolini, Michela
    Fazio, Roberta
    Farinatti, Sara
    Dapra, Valentina
    Santoro, Armando
    Puccini, Alberto
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1489 - 1501
  • [25] First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
    Pietrantonio, Filippo
    Cremolini, Chiara
    Petrelli, Fausto
    Di Bartolomeo, Maria
    Loupakis, Fotios
    Maggi, Claudia
    Antoniotti, Carlotta
    de Braud, Filippo
    Falcone, Alfredo
    Iacovelli, Roberto
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (01) : 156 - 166
  • [26] Safety and efficacy of modified schedula of anti-EGFR monoclonal antibodies plus chemotherapy as first line treatment in metastatic colorectal cancer patients
    Mancarella, S.
    Poti, O.
    De Giorgi, D.
    Schirinzi, M. L.
    De Maria, G.
    Rizzo, A.
    De Benedittis, A.
    Galante, M. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 52 - 52
  • [27] Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer
    Marinho, J.
    Leao, I.
    Neto, E.
    Guedes, H.
    Costa, T.
    Capela, A.
    Moreira Pinto, A.
    Custodio, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S168 - S169
  • [28] Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?
    Triest, Lars
    Debeuckelaere, C.
    Vandamme, T.
    Van Den Heuvel, B.
    Van Den Brande, J.
    Papadimitriou, K.
    Rasschaert, M.
    Prenen, H.
    Peeters, M.
    CURRENT COLORECTAL CANCER REPORTS, 2019, 15 (04) : 130 - 134
  • [29] Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis
    Datian Chen
    Xiang Zhang
    Guangyi Gao
    Lili Shen
    Jiaqi Xie
    Xiaoping Qian
    Huiyu Wang
    World Journal of Surgical Oncology, 16
  • [30] Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis
    Chen, Datian
    Zhang, Xiang
    Gao, Guangyi
    Shen, Lili
    Xie, Jiaqi
    Qian, Xiaoping
    Wang, Huiyu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
12345